(ITOS) – FDA
-
Arcus (ACUS), iTeos Therapeutics (ITOS) Sink as Roche's anti-TIGIT Drug Fails in Phase 3 Trial
-
iTeos Therapeutics (ITOS) Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021
-
Back to ITOS Stock Lookup